Fig. 4.
In vivo differentiative capacity of SL-ICs analyzed by flow cytometry.
Cell surface marker analysis of a representative engrafted NOD/SCID mouse is shown. (A) Six weeks later, bone marrow cells from a NOD/SCID mouse implanted with 105 CD34++CD38−cells from patient No. 5 were analyzed by flow cytometry. Cells were stained with anti–CD45 mAb and the mouse isotype IgG1 control mAb. Viable cells were sorted according to their CD45 expression. (B) The CD45+ gated cells were stained with anti–CD34-FITC, anti–CD38-PE, and anti–CD19-PE mAbs, respectively. (C) Identical cell surface marker analysis was performed on the original blasts of patient No. 5.
